Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Epoetin Alfa

Known as: Erythropoietin, 1-165-Erythropoietin (human clone lambdaHEPOFL13 protein moiety), glycoform alpha, EPO 
A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily… Expand
National Institutes of Health

Related topics

Related topics

33 relations
1 ML Epoetin Alfa 3000 UNT/ML Injection [Procrit]1 ML Epoetin Alfa 4000 UNT/ML Injection [Procrit]AnemiaB-Cell Activation
Expand

Narrower (7)

BinocritEpoetin Alfa HexalEpogenEprex
Expand

Broader (2)

HematinicsRecombinant Erythropoietin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Highly Cited
2007
Highly Cited
2007
Efficacy and safety of epoetin alfa in critically ill patients.
BACKGROUND Anemia, which is common in the critically ill, is often treated with red-cell transfusions, which are associated with… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Highly Cited
2006
Highly Cited
2006
Correction of anemia with epoetin alfa in chronic kidney disease.
BACKGROUND Anemia, a common complication of chronic kidney disease, usually develops as a consequence of erythropoietin… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Review
2005
Review
2005
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
PURPOSE To evaluate the effect on survival and quality of life of maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with… Expand
Highly Cited
2003
Highly Cited
2003
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
BACKGROUND Anaemia is associated with poor cancer control, particularly in patients undergoing radiotherapy. We investigated… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
Highly Cited
2001
Highly Cited
2001
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
PURPOSE This randomized, double-blind, placebo-controlled clinical trial assessed the effects of epoetin alfa on transfusion… Expand
Highly Cited
2000
Highly Cited
2000
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.
Erythropoietin (EPO), recognized for its central role in erythropoiesis, also mediates neuroprotection when the recombinant form… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Highly Cited
1998
Highly Cited
1998
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
PURPOSE To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based… Expand
Highly Cited
1995
Highly Cited
1995
Purification and Characterization of Hypoxia-inducible Factor 1 (*)
  • Guang L. Wang, Gregg L. Semenza
  • The Journal of Biological Chemistry
  • 1995
    • Corpus ID: 41659164
Hypoxia-inducible factor 1 (HIF-1) is a DNA-binding protein that activates erythropoietin (Epo) gene transcription in Hep3B cells… Expand
Highly Cited
1993
Highly Cited
1993
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
  • G. Wang, G. Semenza
  • Proceedings of the National Academy of Sciences…
  • 1993
    • Corpus ID: 28961662
Transcription of the human erythropoietin (EPO) gene is activated in Hep3B cells exposed to hypoxia. Hypoxia-inducible factor 1… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE